3 ms·
The article warns about impending future inequality: > Imagine two employees. One can afford these medications, the other cannot. One has regulated impulses, h
by YokoZar 2y ago
The article warns about impending future inequality:
> Imagine two employees. One can afford these medications, the other cannot. One has regulated impulses, higher energy, better focus, and lower healthcare costs. The other doesn't. In a few years, data shows the first is three times more likely to be promoted.
> Scale that across society.
I'm not sure this is a reasonable worry. Ozempic is going out of patent in less than a year's time. There will be cheap generics all over the place. Purportedly the drug has a very low unit cost and uncomplicated manufacturing process, and every potential generic manufacturer knows it'll be a huge hit. That means we should expect it to rapidly become a commodity that's quite available.
If it really does cut food, alcohol, and cigarette costs so dramatically then I suspect a decent amount of poorer people would budget for the drug even if it didn't become cheap. It's not like poor people don't buy food, alcohol, or cigarettes today -- if it's a net savings and health/life improvement, it's even more worth buying than the alternative.
- jijji 2y agowhen semaglutide and tirzepatide first came out, they were being synthesized in labs across the world for pennies per milligram, as with all compounds.
- glp1guide 2y agoYeah unfortunately that’s about to come to an abrupt end
- jijji 2y agohow so? the last i checked, the prices are going down, not up (from the biolabs that manufacture the peptides)
- glp1guide 2y agoSorry a bit late here, but both Tirzepatide and Semaglutide are off the shortage list, and the promise to not seek legal action that is currently allowing some compounders to operate freely will likely end sometime soon. Literally, the only reason any compounder today (that is brave enough) can produce Tirzepatide or Semaglutide is because the FDA has promised to not pursue legal action for a short period to enable people to find other solutions. Prices are about to go back up/a bunch of options are about to leave the market. See: Novo Nordisk's share price/related news.
- YokoZar 2y agoSure, but shouldn't we expect this to reverse again when it goes out of patent, at least for Ozempic?
- glp1guide 2y agoAbsolutely! Timing on that is not so great though: https://glp1.guide/content/patent-expirations-for-glp1-receptor-agonists/ https://glp1.guide/content/patent-expirations-for-glp1-recep... Again this is not great news but if you zoom out it’s amazing that obesity might be a solved problem basically completely in like 10 years. Obviously GLP1s don’t work for everyone but they work for a lot of people, maybe we can focus the remaining resources on a smaller group of people with greater struggles